Abarelix
GnRH antagonist for advanced prostate cancer. Depot formulation providing sustained testosterone suppression without initial flare, suitable for patients with metastatic disease.
Abarelix is a first-generation GnRH antagonist and a synthetic decapeptide used in the treatment of advanced prostate cancer, particularly castration-resistant (hormone-refractory) prostate cancer. It competitively blocks pituitary GnRH receptors, rapidly suppressing LH and FSH secretion to achieve rapid testosterone reduction to castrate levels, providing swift hormonal ablation therapy.
| Parameter | Specification |
| CAS | 183552-38-7 |
| Molecular Formula | C₇₂H₉₅ClN₁₄O₁₄ |
| Molecular Weight | 1416.06 g/mol |
| Category | GnRH/Reproductive |
| Purity | ≥99% |
| Status | GMP-compliant, FDA-ready |
| Applications | Advanced prostate cancer, hormone-sensitive tumors, testosterone suppression |
| CAS | 183552-38-7 |
|---|---|
| Applications | Advanced Prostate Cancer, Hormone-dependent Tumors, Testosterone Suppression |
Related products
-
Liraglutide
CAS: 204656-20-2Applications: cardiovascular risk reduction, GLP-1, obesity management -
Retatrutide
CAS: 2381089-83-2Applications: Refractory diabetes, Severe obesity, Triple agonist, weight management -
Alarelin
CAS: 79561-22-1Applications: Assisted Reproduction, Endometriosis, Hormone-dependent Tumors, Uterine Fibroids -
Aviptadil
CAS: 40077-57-4Applications: Acute respiratory distress syndrome, ARDS, Lung protection, Pulmonary hypertension, VIP analog